Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.

NCT06335069 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT06335069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06335069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.
Lead sponsor
Maastricht University Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2025
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast diseases, breast neoplasms